December 8, 2025Annals of Internal Medicine

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists

View Full Paper

Ask AI

Bookmark

Authors

AKAlbert KoHarvard University YCYu-Cheng ChangDanbury Hospital FBFurkan BaharBrigham and Women's Hospital

Discussion

Member takes

Implication

Observational analysis suggests glucagon-like peptide-1 receptor agonists may elevate cancer risk, indicating concerns for patients using these treatments.

Key Points

Cancer risk appears elevated with glucagon-like peptide-1 receptor agonists, and ongoing evaluation is necessary.
Significant data limitations persist regarding dual agonists and cancer risk assessment.
Observational analysis presents potential correlations between medication usage and cancer occurrences.
Insight into these risks is vital for clinical guidelines and patient safety considerations.

Cite This Study

Ko et al. (2025) studied this question.

synapsesocial.com/papers/694020e22d562116f28faa34 https://doi.org/10.7326/annals-25-02237

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis suggests glucagon-like peptide-1 receptor agonists may elevate cancer risk, indicating concerns for patients using these treatments.

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists

Discussion

Member takes

Implication

Key Points

Cite This Study

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider